Dr. Gino Corsini Acuña
Science Communication Center
A new CRISPR version developed by Gaudelli et al. reduced the involuntary genomic error rate from 10 to 0.1 percent. The researchers have proved their new technology by correcting genetic errors on blood pathologies (leukemia) which were originated by DNA mutations in the eukaryotic cells.
